Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom.

Samuel Hsiang Lim,Beatriz Gros,Esha Sharma,Anouk Lehmann,James O Lindsay, Louise Caulfield,Daniel R Gaya,Jo Taylor,Jimmy Limdi,Jon Kwok, Elinor Shuttleworth,Anjan Dhar,Gemma Burdge,Christian Selinger, Sara Cococcia,Charles Murray,Karthiha Balendran,Tim Raine,Becky George,Gareth Walker, Robin Aldridge,Peter Irving,Charlie W Lees,Mark Samaan

Inflammatory bowel diseases（2023）

引用 0|浏览19

暂无评分

摘要

Switching to SC vedolizumab appears as effective, safe, and well tolerated as continued IV treatment and maintains comparable disease control and quality of life as IV treatment at 52 weeks.

查看译文

关键词

inflammatory bowel disease,subcutaneous,vedolizumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要